Cite
HARVARD Citation
Patel, J. et al. (2017). Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702. Journal of medical economics. pp. 1121-1122. [Online].